Key result
Coronary artery disease in the transplanted heart is driven by immune-mediated inflammation and endothelial injury, with retransplantation remaining the only definitive but controversial treatment.
Population
Patients with a transplanted heart developing coronary artery disease (cardiac allograft vasculopathy)
Design
Review
Authors
Loading...
May prompt enhanced post-transplant immunomodulation; leaves open whether targeted therapies can delay retransplantation.
Cardiac allograft vasculopathy is driven by complex immune and inflammatory responses, with limited treatment options beyond ethically controversial retransplantation.
Weis et al. (2000) conducted a review in Coronary artery disease in the transplanted heart. Coronary artery disease in the transplanted heart is driven by immune-mediated inflammation and endothelial injury, with retransplantation remaining the only definitive but controversial treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: